Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Medical College of Nanchang University, Nanchang, Jiangxi 330000, China.
J Biochem. 2020 Jun 1;167(6):557-564. doi: 10.1093/jb/mvaa012.
Colon cancer side population (SP) cells are a small subset of cancer cells that have cancer stemness capacity and enhanced drug resistance. ABCG2 is a multidrug resistance-related protein in SP cells and has been demonstrated to be regulated by Notch signalling pathway. Recently, microRNAs are reported to play a critical role in SP cell fate. However, their role in ABCG2-mediated drug resistance in colon cancer SP cells remains unclear. In the current study, the different expressions of miR-552, miR-611, miR-34a and miR-5000-3p were compared within SP and non-SP cells, which were separated from human colon cancer cell lines (SW480 and LoVo). We found that miR-34a was significantly down-regulated in SP cells and that overexpressing miR-34a overcame drug resistance to 5-fluorouracil (5-FU). The luciferase reporter assay indicated that miR-34a negatively regulated DLL1, a ligand of Notch signalling pathway, via binding with 3'-untranslated region of its messenger RNA. In addition, overexpressing miR-34a overcame ABCG2-mediated resistance to 5-FU via DLL1/Notch pathway in vitro, and suppressed tumour growth under 5-FU treatment in vivo. In conclusion, our findings suggest that miR-34a acts as a tumour suppressor via enhancing chemosensitivity to 5-FU in SP cells, which provides a novel therapeutic target in chemotherapy-resistant colon cancer.
结肠癌侧群(SP)细胞是一小部分具有癌症干性能力和增强耐药性的癌细胞。ABCG2 是 SP 细胞中一种多药耐药相关蛋白,已被证明受 Notch 信号通路调节。最近,microRNAs 被报道在 SP 细胞命运中发挥关键作用。然而,它们在结肠癌 SP 细胞中 ABCG2 介导的药物耐药中的作用尚不清楚。在本研究中,比较了从人结肠癌细胞系(SW480 和 LoVo)中分离的 SP 和非 SP 细胞中 miR-552、miR-611、miR-34a 和 miR-5000-3p 的不同表达。我们发现 miR-34a 在 SP 细胞中显著下调,过表达 miR-34a 可克服 5-氟尿嘧啶(5-FU)的耐药性。荧光素酶报告基因检测表明,miR-34a 通过结合其信使 RNA 的 3'-非翻译区,负调控 Notch 信号通路的配体 DLL1。此外,过表达 miR-34a 通过 DLL1/Notch 通路在体外克服 ABCG2 介导的 5-FU 耐药性,并在体内 5-FU 治疗下抑制肿瘤生长。总之,我们的研究结果表明,miR-34a 通过增强 SP 细胞对 5-FU 的化疗敏感性发挥肿瘤抑制作用,为化疗耐药性结肠癌提供了一个新的治疗靶点。